References of "Daly, Adrian"
     in
Bookmark and Share    
See detailPituitary Diseases in Daily Clinical Pratice : Prevalence and Relevance 2006
Jaffrain-Réa, M. L.; Valle, L.; Daly, Adrian ULg et al

in Congrès Italien d'Endocrinologie : Florence, 2006 (2006)

Detailed reference viewed: 3 (0 ULg)
See detailEndocrine abnormalities in McCune-Albright syndrome
Tamagno, G.; Petrossians, Patrick ULg; Daly, Adrian ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 5 (0 ULg)
See detailLes patients acromégales sont-il mal pris en charge? De la mauvaise utilisation des bases de données
Petrossians, Patrick ULg; Tichomirova, M.; Daly, Adrian ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 22 (1 ULg)
See detailThe Liège Acromegaly Survey
Tichomirova, M.; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 10 (2 ULg)
See detailIdentification d'une famille porteuse d'une nouvelle mutation bêta-LH accompagnée d'hypogonadisme
Daly, Adrian ULg; Salvi, R.; Ménagé, J.-J. et al

in 23ème Congrès de la Société Française d'Endocrinologie - Abstract book (2006)

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailPathologie inflammatoire de l'hypophyse et grossesse
Hansen, Isabelle ULg; Vroonen, Laurent ULg; Tichomirova, M. et al

in Pathologie hypophysaire et grossesse (2006)

Les affections hypophysaires, tumorales ou non tumorales, sont classiquement responsables d'infertilité. Grâce aux progrès des traitements médicaux et chirurgicaux développés pour le traitement de ces ... [more ▼]

Les affections hypophysaires, tumorales ou non tumorales, sont classiquement responsables d'infertilité. Grâce aux progrès des traitements médicaux et chirurgicaux développés pour le traitement de ces affections hypophysaires, les grossesses sont de plus en plus fréquentes chez les patientes ayant en particulier un adénome hypophysaire sécrétant ou une insuffisance anté-hypophysaire ou un diabète insipide central. Cependant, les conséquences de l'affection hypophysaire et des traitements pour la mère ou le f¿tus sont toujours discutés par les endocrinologues, les gynécologues, les obstétriciens et les pédiatres. Le but de cet ouvrage unique en français est une mise au point de nos connaissances sur le sujet, et tout particulièrement sur le diagnostic hormonal et radiologique d'un syndrome d'hypersécrétion ou d'une insuffisance hypophysaire au cours d'une grossesse, ainsi que sur la prise en charge des patientes présentant une pathologie hypophysaire tumorale ou non tumorale, désirant ou présentant une grossesse. [less ▲]

Detailed reference viewed: 84 (2 ULg)
Full Text
Peer Reviewed
See detailComment j'explore... Une valeur élevée de calcitonine?
Rikir, Estelle ULg; Valdes Socin, Hernan Gonzalo ULg; Vroonen, Laurent ULg et al

in Revue Médicale de Liège (2006), 61(3), 195-200

This article describes a case of lung cancer with associated hypercalcitoninemia in a man with a goitre. The case raises the problem of the differential diagnosis between medullary thyroid carcinoma and a ... [more ▼]

This article describes a case of lung cancer with associated hypercalcitoninemia in a man with a goitre. The case raises the problem of the differential diagnosis between medullary thyroid carcinoma and a neuroendocrine neoplasm with ectopic calcitonin secretion. The article first reviews the physiology of calcitonin, then outlines the diagnostic tests that are required to investigate hypercalcitoninemia and finally discusses the interpretation of test results. [less ▲]

Detailed reference viewed: 116 (8 ULg)
See detailA multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings
Tikhomirova, M.; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 15th Meeting of the Belgian Endocrine Society : Bruxelles, 26 novembre 2005 (2005, November)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailTreatment of pituitary tumors: somatostatin.
Tichomirowa, M. A.; Daly, Adrian ULg; Beckers, Albert ULg

in Endocrine (2005), 28(1), 93-99

Somatostatin is an important physiological regulator of neuroendocrine function across multiple biological systems, including the brain and the gastrointestinal tract. In the pituitary gland, somatostatin ... [more ▼]

Somatostatin is an important physiological regulator of neuroendocrine function across multiple biological systems, including the brain and the gastrointestinal tract. In the pituitary gland, somatostatin regulates the secretion of hormones such as growth hormone and thyroid-stimulating hormone in healthy and pathological states. The short half-life of somatostatin makes it unsuitable for clinical use in chronic diseases, which led to the development of long-acting somatostatin analogs for the treatment of acromegaly and thyroid-stimulating hormone-secreting adenomas, which were administered by intermittent injection twice or three times a day. More recently, depot versions have been developed that permit dosing once every month. This review assesses the efficacy of somatostatin analogs in the treatment of pituitary adenomas, including acromegaly, thyroid-stimulating hormone-secreting tumors, non-functioning adenomas, and Cushing's disease. [less ▲]

Detailed reference viewed: 20 (6 ULg)
Full Text
Peer Reviewed
See detailPredictors and rates of treatment-resistant tumor growth in acromegaly
Besser, G. M.; Burman, P.; Daly, Adrian ULg

in European Journal of Endocrinology (2005), 153(2), 187-193

Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of ... [more ▼]

Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of treatment-resistant pituitary tumor growth remains relatively under-explored. Methods: We assessed the literature for relevant data regarding the surgical, medical and radio-therapeutic treatment of acromegaly in order to identify the factors that were predictive of aggressive or treatment-resistant pituitary tumor behavior in acromegaly and undertook an assessment of the rates of failure to control tumor progression with available treatment modalities. Results: Young age at diagnosis, large tumor size, high growth hormone secretion and certain histological markers are predictors of future aggressive tumor behavior in acromegaly. Significant tumor regrowth occurs in less than 10% of cases thought to be cured surgically, whereas failure to control tumor growth is seen in less than 1% of patients receiving radiotherapy. Somatostatin analogs induce a variable degree of tumor shrinkage in acromegaly but up to 2.2% of somatostatin analog-treated tumors continue to grow. Relative to other therapies, limited data are available for pegvisomant, but these indicate that persistent tumor growth occurs in 1.6-2.9% of cases followed up regularly with serial magnetic resonance imaging scans. Conclusions: Treatment-resistant tumor progression occurs in a small minority of patients with acromegaly, regardless of treatment modality. Young patients with large tumors or those with high pre-treatment levels of growth hormone particularly warrant close monitoring for continued tumor progression during treatment for acromegaly. [less ▲]

Detailed reference viewed: 4 (0 ULg)
Full Text
See detailAcromegaly - Pathology, diagnosis and treatment
van der Lely, A. J.; Beckers, Albert ULg; Daly, Adrian ULg et al

Book published by Taylor and Francis Group (2005)

This book reviews the pathophysiology and physical manifestations of acromegaly and discusses the multiple treatment options now available for the management of the patient with acromegaly. The book ... [more ▼]

This book reviews the pathophysiology and physical manifestations of acromegaly and discusses the multiple treatment options now available for the management of the patient with acromegaly. The book contains an ample number of illustrations that help to emphasize points of particular interest, including radiological, histopathological, and physical diagnosis images. Sections are devoted to detailing important topics including determinants of pathological effects of disease activity in acromegaly, individual therapeutic choices and criteria for diagnosis, and disease control. [less ▲]

Detailed reference viewed: 73 (2 ULg)
See detailMale Hypogonadism caused by isolated luteinizing hormone deficiency
Daly, Adrian ULg; Salvi, R.; Petrossians, Patrick ULg et al

in 37th International symposium - GH and Growth Factors in Endocrinology and Metabolism (Athènes Symposium) (2005)

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailThe Epidemiology of Prolactinomas
Ciccarelli, A.; Daly, Adrian ULg; Beckers, Albert ULg

in Pituitary (2005), 8(1), 3-6

Prolactin-secreting tumors (prolactinomas), the most frequently occurring pituitary tumor, have a frequency that varies with age and sex. They occur most frequently in females aged 20 to 50 years old, at ... [more ▼]

Prolactin-secreting tumors (prolactinomas), the most frequently occurring pituitary tumor, have a frequency that varies with age and sex. They occur most frequently in females aged 20 to 50 years old, at which time the female-to-male ratio is approximately 10:1. In the pediatric-adolescent age group, prolactinomas have a prevalence of 100/million population, and account for less than 2% of all intracranial tumors. Prolactinomas occur in approximately 30% of patients with multiple endocrine neoplasia type 1 and in this setting, they may be more aggressive than their sporadic counterparts. Patients with Carney complex or McCune-Albright syndrome may exhibit hyperprolactinemia due to a pituitary tumor derived from somatomammotropic cells that secrete both growth hormone and prolactin. Few familial cases of prolactinoma unrelated to MEN-1 are reported in literature. [less ▲]

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailGross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
Petrossians, Patrick ULg; Borges-Martins, L.; Espinoza, C. et al

in European Journal of Endocrinology (2005), 152(1), 61-66

Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60 ... [more ▼]

Introduction: Invasive GH-secreting pituitary adenomas are rarely cured by surgery and although long-term therapy with somatostatin analogs (SSAs) may be employed, hormonal control is achieved in only 60% of cases. The impact of tumor debulking on subsequent control of acromegaly with SSAs has not been studied previously. Methods: We studied retrospectively the response to SSA therapy in acromegalic patients before and after incomplete surgical tumor excision. A case review identified 24 acromegalic patients who had received SSA therapy for 1 month before and after gross total resection or debulking of adenomas. No patient received radiotherapy or combination treatment with SSAs and dopamine agonists during the study. GH and IGF-I responses to SSAs were recorded pre- and postoperatively. Postoperative SSA therapy was begun after a washout period of 1–3 months to assess the hormonal effects of the surgery alone. Results: Before preoperative SSA treatment, 24/24 (100%) patients had elevated GH levels and IGF-I levels were elevated in 19/21 (90.5%) patients with recorded values. During preoperative SSA treatment, GH and IGF-I levels were normalized in 7/24 (29.2%) and 11/24 (45.8%) patients respectively. Following postoperative washout, GH was controlled in only 3/24 (12.5%) patients, while IGF-I was controlled in 8/19 (42.1%) patients with available data. During the second SSA treatment period, normal GH levels were seen in 13/24 (54.2%) patients, while IGF-I control was noted in 18/23 (78.3%). Conclusion: Gross total tumor resection or debulking increases the likelihood of achieving biochemical disease control with SSAs in acromegalic patients with adenomas that were not amenable to complete surgical resection and in whom primary SSA therapy was unable to achieve good biochemical control. [less ▲]

Detailed reference viewed: 41 (1 ULg)
Full Text
Peer Reviewed
See detailDesloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique.
Wang, Y. H.; Tache, Y.; Harris, A. G. et al

in Allergy (2005), 60(1), 117-24

BACKGROUND: Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. Desloratadine inhibits the release of allergic inflammatory mediators ... [more ▼]

BACKGROUND: Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. Desloratadine inhibits the release of allergic inflammatory mediators in vitro. We studied the impact of desloratadine on mast cell degranulation due to activation and re-activation by the secretagogue, compound 48/80. METHODS: Rat peritoneal eluate containing 5-6% mast cells were activated by a low concentration of compound 48/80 in a medium containing the vital fluorescent dye, Sulforhodamine-B (SFRM-B, 200 microg/ml), which is engulfed by activated mast cells. The fluorescent image of activated mast cells was captured digitally and the total fluorescent area was analyzed when desloratadine was applied before or after compound 48/80. RESULTS: Mast cells were not activated by desloratadine (10(-4) M), SFRM-B (200 microg/ml), or diluent alone. A low concentration of compound 48/80 (0.125 microg/ml) induced fluorescence, while mast cells lost fluorescent images due to further degranulation on re-exposure to compound 48/80. Desloratadine (10(-8)-10(-4) M), inhibited compound 48/80-induced mast cell degranulation in a concentration-dependent manner. Desloratadine also reduced the loss of fluorescent images due to re-exposure to compound 48/80. CONCLUSIONS: Desloratadine may have a mast cell stabilizing effect at low concentrations in response to repeated mast cell activation in vitro. [less ▲]

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailCytokine dysregulation, inflammation and well-being
Elenkov, I. J.; Iezzoni, D. G.; Daly, Adrian ULg et al

in Neuroimmunomodulation (2005), 12(5), 255-269

Cytokines mediate and control immune and inflammatory responses. Complex interactions exist between cytokines, inflammation and the adaptive responses in maintaining homeostasis, health, and well-being ... [more ▼]

Cytokines mediate and control immune and inflammatory responses. Complex interactions exist between cytokines, inflammation and the adaptive responses in maintaining homeostasis, health, and well-being. Like the stress response, the inflammatory reaction is crucial for survival and is meant to be tailored to the stimulus and time. A full-fledged systemic inflammatory reaction results in stimulation of four major programs: the acute-phase reaction, the sickness syndrome, the pain program, and the stress response, mediated by the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Common human diseases such as atopy/allergy, autoimmunity, chronic infections and sepsis are characterized by a dysregulation of the pro-versus anti-inflammatory and T helper (Th)1 versus Th2 cytokine balance. Recent evidence also indicates the involvement of pro-inflammatory cytokines in the pathogenesis of atherosclerosis and major depression, and conditions such as visceral-type obesity, metabolic syndrome and sleep disturbances. During inflammation, the activation of the stress system, through induction of a Th2 shift, protects the organism from systemic 'overshooting' with Th1/pro-inflammatory cytokines. Under certain conditions, however, stress hormones may actually facilitate inflammation through induction of interleukin (IL)-1, IL-6, IL-8, IL-18, tumor necrosis factor-alpha and C-reactive protein production and through activation of the corticotropin-releasing hormone/substance P-histamine axis. Thus, a dysfunctional neuroendocrine-immune interface associated with abnormalities of the 'systemic anti-inflammatory feedback' and/or 'hyperactivity' of the local pro-inflammatory factors may play a role in the pathogenesis of atopic/allergic and autoimmune diseases, obesity, depression, and atherosclerosis. These abnormalities and the failure of the adaptive systems to resolve inflammation affect the well-being of the individual, including behavioral parameters, quality of life and sleep, as well as indices of metabolic and cardiovascular health. These hypotheses require further investigation, but the answers should provide critical insights into mechanisms underlying a variety of common human immune-related diseases. Copyright (C) 2005 S. Karger AG, Basel. [less ▲]

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailAn overview of the epidemiology and genetics of acromegaly.
Daly, Adrian ULg; Petrossians, Patrick ULg; Beckers, Albert ULg

in Journal of Endocrinological Investigation (2005), 28(11 Suppl International), 67-69

Historical data indicate that pituitary tumors represent 10% of intracranial tumors, while adenomas are noted in approximately 14-23% of normal subjects on autopsy or magnetic resonance imaging (MRI ... [more ▼]

Historical data indicate that pituitary tumors represent 10% of intracranial tumors, while adenomas are noted in approximately 14-23% of normal subjects on autopsy or magnetic resonance imaging (MRI). About 2.5% of these tumors stain positive for GH in histopathologic studies. In contrast, the prevalence of clinically diagnosed acromegaly is lower at 36-69 per million population. Ongoing studies indicate that the actual prevalence of acromegaly in the community may be higher than previous epidemiologic data suggest. Acromegaly can occur both sporadically and in the setting of familial conditions, such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Isolated familial somatotropinoma has been described and newer data suggest that acromegaly may also occur in non-MEN1/CNC families in combination with other pituitary tumor phenotypes. [less ▲]

Detailed reference viewed: 49 (16 ULg)
Full Text
See detailControl of tumor size and hormonal hypersecretion in acromegaly : a large single-center experience
Daly, Adrian ULg; Tikhomirova, M.; Petrossians, Patrick ULg et al

in European Congress of Endocrinology - Abstract book (2005)

Detailed reference viewed: 9 (1 ULg)
See detailA multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings
Daly, Adrian ULg; Petrossians, Patrick ULg; Murat, A. et al

in 9th International Pituitary Congress - Abstract book (2005)

Detailed reference viewed: 7 (0 ULg)
See detailDiagnosis of active acromegaly : is it time to amend the consensus of opinions?
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in International Novartis Workshop - somatostatin and its natural and synthetic analogues - Update from basic to clinical aspects - Abstract book (2005)

Detailed reference viewed: 4 (0 ULg)